I'rom Group to buy CMAX Pty Ltd from IDT Australia, page-13

Hopefully Mayne Pharma would be putting out some attractive parcel deals at the pharmacy level to create a sales pipeline for Temozolomide. With generics you need to get new products on the shelf by offering attractive margins in the first instance. By parcelling it in with some of their better selling products is a way of doing this. If the sell in strategy works well a large volume of stock is needed up front. You are probably right Morley that unless the launch happens in the next week or two we will not see any revenue in the first half except some milestone payments that will be coming from Mayne.